title: Fluvastin therapy affects TAFI concentration in kidney transplant recipients.
abstract: Thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein, linking coagulation and fibrinolysis. Recently, attention has been drawn to the beneficial effects of statins on haemostasis in kidney patients prone to dyslipidaemia and with a high risk of cardiovascular death. The purpose of this study was to assess whether fluvastatin affects TAFI concentration in renal transplant recipients. We evaluated thrombin-antithrombin (TAT) complexes, prothrombin fragments 1+2, thrombomodulin, plasmin-antiplasmin (PAP) complexes, TAFI, P-selectin, and lipoprotein (a), 1, 2, and 3 months before and after fluvastatin treatment and in normolipaemic kidney transplant recipients and healthy volunteers. Cholesterol and LDL fell significantly as soon as 1 month after treatment had begun and remained lowered during the therapy. TAFI and prothrombin fragments 1+2 decreased significantly after 3 months of fluvastatin administration, whereas P-selectin decreased significantly after 2 months and remained significantly lower after 3 months of this therapy. We can conclude that fluvastatin is an effective hypolipaemic agent that favourably affects haemostasis.
authors.affiliation: Department of Nephrology and Internal Medicine, Medical Academy Bialystok, Zurawia 14, 15-540 Bialystok, Poland.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Malyszko
authors.forename: Jacek S
authors.initials: JS
authors.lastname: Malyszko
authors.forename: Michal
authors.initials: M
authors.lastname: Mysliwiec
mesh_terms: D000328:Adult; D000990:Antithrombin III; D025901:Carboxypeptidase B2 / Q000097:blood*; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage*; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism; D000077340:Fluvastatin; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage*; D016030:Kidney Transplantation; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010447:Peptide Hydrolases / Q000097:blood; D011498:Protein Precursors / Q000097:blood; D011516:Prothrombin
chemical_list: D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D008055:Lipids; D019007:P-Selectin; D010446:Peptide Fragments; D011498:Protein Precursors; C046193:antithrombin III-protease complex; D000077340:Fluvastatin; C029733:prothrombin fragment 1; C044183:prothrombin fragment 2; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases; D025901:Carboxypeptidase B2; D005341:Fibrinolysin